Real-world evidence shows 34% reduction in risk of death with Ibrance in metastatic breast cancers
- Recently published data have shown Ibrance (palbociclib) in combination with letrozole being associated with improved real-world progression-free survival and overall survival in women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer
- These data indicate a 42% reduction in the risk of progression and a 34% reduction in the risk of death when taking Ibrance in combination with letrozole as opposed to letrozole alone
- “Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials,”
Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
About DISTILL
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
Ref: RWEAPR2022GSA